Allergan has announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan’s pending acquisition of Vitae Pharmaceuticals, a Fort Washington, Pennsylvania-based clinical-stage biotechnology company.

The expiration of the waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter of 2016. Allergan announced the acquisition of Vitae in September 2016 for $21.00 per share, in cash, for a total transaction value of approximately $639 million at the time of the announcement.

Source: Allergan